{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:23:50Z","timestamp":1781043830849,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.omtm.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T06:21:05Z","timestamp":1542867665000},"page":"86-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["AAV2\/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization"],"prefix":"10.1016","volume":"13","author":[{"given":"Chris P.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.J.","family":"O\u2019Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Gatherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"McClements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"MacLaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Goverdhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Glennie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lotery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2018.11.005_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/path.4266","article-title":"Mechanisms of age-related macular degeneration and therapeutic opportunities","volume":"232","author":"van Lookeren Campagne","year":"2014","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.omtm.2018.11.005_bib2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1377\/hlthaff.2013.0832","article-title":"Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period","volume":"33","author":"Hutton","year":"2014","journal-title":"Health Aff. (Millwood)"},{"key":"10.1016\/j.omtm.2018.11.005_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19780","article-title":"A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)","volume":"19","author":"Chakravarthy","year":"2015","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.omtm.2018.11.005_bib4","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial","volume":"386","author":"Rakoczy","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2018.11.005_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/hum.2006.17.167","article-title":"Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial","volume":"17","author":"Campochiaro","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2018.11.005_bib6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/mt.2014.3","article-title":"Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in\u00a0vivo","volume":"22","author":"Cesana","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2018.11.005_bib7","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ymthe.2005.12.001","article-title":"Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors","volume":"13","author":"Stieger","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2018.11.005_bib8","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1089\/hum.2011.090","article-title":"Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab","volume":"22","author":"Mao","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2018.11.005_bib9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jgm.2678","article-title":"Reduction of choroidal neovascularization in mice by adeno-associated virus-delivered anti-vascular endothelial growth factor short hairpin RNA","volume":"14","author":"Askou","year":"2012","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2018.11.005_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ymthe.2005.04.022","article-title":"Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys","volume":"12","author":"Lai","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2018.11.005_bib11","doi-asserted-by":"crossref","first-page":"e19078","DOI":"10.1371\/journal.pone.0019078","article-title":"A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration","volume":"6","author":"Cashman","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2018.11.005_bib12","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2018.11.005_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jgm.1126","article-title":"Novel AAV serotypes for improved ocular gene transfer","volume":"10","author":"Lebherz","year":"2008","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.omtm.2018.11.005_bib14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1167\/iovs.13-11821","article-title":"Fc\u03b3 receptor upregulation is associated with immune complex inflammation in the mouse retina and early age-related macular degeneration","volume":"55","author":"Murinello","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2018.11.005_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-bioeng-071114-040733","article-title":"Advances in Antibody Design","volume":"17","author":"Tiller","year":"2015","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.omtm.2018.11.005_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/toxsci\/52.1.101","article-title":"Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation","volume":"52","author":"Mordenti","year":"1999","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.omtm.2018.11.005_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10456-012-9302-0","article-title":"Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications","volume":"16","author":"Stahl","year":"2013","journal-title":"Angiogenesis"},{"key":"10.1016\/j.omtm.2018.11.005_bib18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ajo.2014.05.037","article-title":"Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I\/II study","volume":"158","author":"Souied","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2018.11.005_bib19","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1517\/14712598.2014.937701","article-title":"Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development","volume":"14","author":"Kovaleva","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtm.2018.11.005_bib20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1074\/jbc.M508199200","article-title":"Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF","volume":"281","author":"Liang","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2018.11.005_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtm.2018.11.005_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0378-1119(89)90209-6","article-title":"Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5","volume":"79","author":"Miyazaki","year":"1989","journal-title":"Gene"},{"key":"10.1016\/j.omtm.2018.11.005_bib23","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1128\/jvi.70.7.4345-4351.1996","article-title":"The hepatitis B virus posttranscriptional regulatory element is composed of two subelements","volume":"70","author":"Donello","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2018.11.005_bib24","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1167\/iovs.07-1194","article-title":"Effects of\u00a0an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes","volume":"49","author":"Campa","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2018.11.005_bib25","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2018.11.005_bib26","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0002-9440(10)65753-7","article-title":"Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model","volume":"153","author":"Tobe","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtm.2018.11.005_bib27","doi-asserted-by":"crossref","first-page":"11372","DOI":"10.1128\/JVI.01327-07","article-title":"Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors","volume":"81","author":"Allocca","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2018.11.005_bib28","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1167\/iovs.10-6295","article-title":"Suppression of choroidal neovascularization by vasohibin-1, a vascular endothelium-derived angiogenic inhibitor","volume":"52","author":"Wakusawa","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2018.11.005_bib29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1189\/jlb.1110603","article-title":"IL-27 inhibits pathophysiological intraocular neovascularization due to laser burn","volume":"91","author":"Hasegawa","year":"2012","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.omtm.2018.11.005_bib30","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.4049\/jimmunol.178.3.1783","article-title":"CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration","volume":"178","author":"Bora","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2018.11.005_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/bjophthalmol-2012-302307","article-title":"Intravitreal human complement factor H in a rat model of laser-induced choroidal neovascularisation","volume":"97","author":"Kim","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2018.11.005_bib32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0303-7207(92)90152-V","article-title":"The use of the amplifiable high-expression vector pEE14 to study the interactions of autoantibodies with recombinant human thyrotrophin receptor","volume":"83","author":"Harfst","year":"1992","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.omtm.2018.11.005_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0042-6989(85)90076-8","article-title":"A schematic eye for the mouse, and comparisons with the rat","volume":"25","author":"Remtulla","year":"1985","journal-title":"Vision Res."},{"key":"10.1016\/j.omtm.2018.11.005_bib34","doi-asserted-by":"crossref","first-page":"e0128418","DOI":"10.1371\/journal.pone.0128418","article-title":"A Quantitative and Standardized Method for the Evaluation of Choroidal Neovascularization Using MICRON III Fluorescein Angiograms in Rats","volume":"10","author":"Wigg","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2018.11.005_bib35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050118301177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050118301177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:23:30Z","timestamp":1762421010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050118301177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":35,"alternative-id":["S2329050118301177"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2018.11.005","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV2\/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019","name":"copyright","label":"Copyright"}]}}